170 related articles for article (PubMed ID: 25975377)
21. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.
Fults D; Brockmeyer D; Tullous MW; Pedone CA; Cawthon RM
Cancer Res; 1992 Feb; 52(3):674-9. PubMed ID: 1346255
[TBL] [Abstract][Full Text] [Related]
22. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
Buccoliero AM; Castiglione F; Degl'Innocenti DR; Gheri CF; Genitori L; Taddei GL
Fetal Pediatr Pathol; 2012 Oct; 31(5):278-82. PubMed ID: 22432788
[TBL] [Abstract][Full Text] [Related]
23. Exploring the distinctive biological characteristics of pilocytic and low-grade diffuse astrocytomas using microarray gene expression profiles.
Rorive S; Maris C; Debeir O; Sandras F; Vidaud M; Bièche I; Salmon I; Decaestecker C
J Neuropathol Exp Neurol; 2006 Aug; 65(8):794-807. PubMed ID: 16896313
[TBL] [Abstract][Full Text] [Related]
24. Role of gemistocytes in astrocytoma progression.
Watanabe K; Tachibana O; Yonekawa Y; Kleihues P; Ohgaki H
Lab Invest; 1997 Feb; 76(2):277-84. PubMed ID: 9042164
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis.
Appin CL; Brat DJ
Adv Anat Pathol; 2015 Jan; 22(1):50-8. PubMed ID: 25461780
[TBL] [Abstract][Full Text] [Related]
26. Analysis of the IDH1 codon 132 mutation in brain tumors.
Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
[TBL] [Abstract][Full Text] [Related]
27. p53 abnormality and tumor invasion in patients with malignant astrocytoma.
Momota H; Narita Y; Matsushita Y; Miyakita Y; Shibui S
Brain Tumor Pathol; 2010 Oct; 27(2):95-101. PubMed ID: 21046311
[TBL] [Abstract][Full Text] [Related]
28. Multiple deleted regions on the long arm of chromosome 6 in astrocytic tumours.
Miyakawa A; Ichimura K; Schmidt EE; Varmeh-Ziaie S; Collins VP
Br J Cancer; 2000 Feb; 82(3):543-9. PubMed ID: 10682663
[TBL] [Abstract][Full Text] [Related]
29. Genetic alterations associated with glioma progression.
Kleihues P; Lübbe J; Watanabe K; von Ammon K; Ohgaki H
Verh Dtsch Ges Pathol; 1994; 78():43-7. PubMed ID: 7534015
[TBL] [Abstract][Full Text] [Related]
30. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
Seiz M; Tuettenberg J; Meyer J; Essig M; Schmieder K; Mawrin C; von Deimling A; Hartmann C
Acta Neuropathol; 2010 Aug; 120(2):261-7. PubMed ID: 20514489
[TBL] [Abstract][Full Text] [Related]
31. Alterations of the RRAS and ERCC1 genes at 19q13 in gemistocytic astrocytomas.
Ohta T; Kim YH; Oh JE; Satomi K; Nonoguchi N; Keyvani K; Pierscianek D; Sure U; Mittelbronn M; Paulus W; Vital A; Yokoo H; McDonald K; Kleihues P; Nazaret N; Barbet F; Lachuer J; Ohgaki H
J Neuropathol Exp Neurol; 2014 Oct; 73(10):908-15. PubMed ID: 25192052
[TBL] [Abstract][Full Text] [Related]
32. Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status.
Hyare H; Rice L; Thust S; Nachev P; Jha A; Milic M; Brandner S; Rees J
Eur J Radiol; 2019 May; 114():120-127. PubMed ID: 31005161
[TBL] [Abstract][Full Text] [Related]
33. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma.
Sahm F; Reuss D; Koelsche C; Capper D; Schittenhelm J; Heim S; Jones DT; Pfister SM; Herold-Mende C; Wick W; Mueller W; Hartmann C; Paulus W; von Deimling A
Acta Neuropathol; 2014 Oct; 128(4):551-9. PubMed ID: 25143301
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation.
Goeppert B; Schmidt CR; Geiselhart L; Dutruel C; Capper D; Renner M; Vogel MN; Zachskorn C; Zinke J; Campos B; Schmezer P; Popanda O; Wick W; Weller M; Meyermann R; Schittenhelm J; Harter PN; Simon P; Weichert W; Schirmacher P; Plass C; Mittelbronn M
J Neuropathol Exp Neurol; 2013 Oct; 72(10):933-41. PubMed ID: 24042196
[TBL] [Abstract][Full Text] [Related]
35. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
[TBL] [Abstract][Full Text] [Related]
36. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
[TBL] [Abstract][Full Text] [Related]
37. The definition of primary and secondary glioblastoma.
Ohgaki H; Kleihues P
Clin Cancer Res; 2013 Feb; 19(4):764-72. PubMed ID: 23209033
[TBL] [Abstract][Full Text] [Related]
38. Molecular markers relating to malignant progression in Grade II astrocytoma.
Yue WY; Yu SH; Zhao SG; Chen ZP
J Neurosurg; 2009 Apr; 110(4):709-14. PubMed ID: 19025355
[TBL] [Abstract][Full Text] [Related]
39. Detection of a novel point mutation in the p53 gene in grade II astrocytomas by PCR-SSCP analysis with additional Klenow treatment.
Chawengchao B; Petmitr S; Ponglikitmongkol M; Chanyavanich V; Sangruji T; Theerapuncharoen V; Hayashi K; Thangnipon W
Anticancer Res; 2001; 21(4A):2739-43. PubMed ID: 11724349
[TBL] [Abstract][Full Text] [Related]
40. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
